Age-related non-AIDS comorbidities (NACM) increasingly account for morbidity and mortality in persons living with HIV. The burden of NACM and its association with HIV is poorly described in women.
Among those with a normal baseline BMI, the adjusted mean change in BMI at 12 months was smaller with EVG/c, bDRV, and RAL than DTG (range -0.26 to -0.27). Among overweight PLWH, the adjusted mean BMI increase was statistically smaller with bDRV than DTG (-0.32, Figure 4 ). Results were consistent in IPCW estimates.
Conclusion. The majority of PLWH on stable ART in this US-based cohort were overweight/obese at the time of switch to the regimens of interest. Small mean increases in BMI for all regimens were noted over time, for which the clinical significance is not yet known. Apparent differences in BMI changes favoring EVG/c, RAL, and bDRV vs. DTG over the short term were largely attenuated with longer follow-up, with significant differences mainly observed in those with a normal BMI at baseline. Friday, October 4, 2019: 11:15 AM Background. Switching from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) containing antiretroviral therapy (ART) can preserve or improve renal function as well as bone mineral density in patients living with HIV infection (PLWH). The switch can also negatively influence cholesterol, but potential changes in body mass index (BMI) and atherosclerotic cardiovascular disease (ASCVD) risk are unknown.
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